Skip to main content

Table 1 Correlations between clinicopathological characteristics and RBM3 mRNA (Cohort I) levels and protein expression (Cohort II)

From: Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer

  Cohort I   Cohort II   
RBM3 score low high   0 1 2  
n (% for columns) 120 (45.6) 143 (54.4) p-value 74 (49.0) 50 (33.1) 27 (17.9) p-value
Histological subtype       
mucinuos 0 (0.0) 0 (0.0) 0.887 4 (5.4) 4 (8.0) 3 (11.1) 0.395
serous 111 (92.5) 133 (93.0)   42 (56.8) 31 (62.0) 16 (59.3)  
endometroid 9 (7.5) 9 (6.3)   17 (23.0) 12 (24.0) 5 (18.5)  
clear cell 0 (0.0) 0 (0.0)   6 (8.1) 1 (2.0) 2 (7.4)  
Brenner 0 (0.0) 0 (0.0)   0 (0.0) 0 (0.0) 1 (3.7)  
adenocarcinoma nos 0 (0.0) 1 (0.7)   5 (6.8) 2 (4.0) 0 (0.0)  
Differentiation grade        
high 3 (2.5) 14 (9.8) 0.079 2 (2.7) 2 (4.0) 3 (11.1) 0.084
intermediate 40 (33.3) 48 (33.6)   17 (23.0) 13 (26.0) 9 (33.3)  
low 77 (64.2) 78 (54.5)   55 (74.3) 35 (70.0) 15 (55.6)  
missing 0 (0.0) 3 (2.1)   0 (0.0) 0 (0.0) 0 (0.0)  
Stage        
I 9 (7.5) 15 (10.5) 0.070 14 (18.9) 7 (14.0) 5 (18.5) 0.760
II 3 (2.5) 15 (10.5)   5 (6.8) 9 (18.0) 3 (11.1)  
III 101 (84.2) 104 (72.7)   40 (54.1) 26 (52.0) 8 (29.6)  
IV 7 (5.8) 9 (6.3)   9 (12.2) 6 (12.0) 7 (25.9)  
missing 0 (0.0) 0 (0.0)   6 (8.1) 2 (4.0) 4 (14.8)  
  1. Correlations were calculated using Spearman correlation test unless other specified.
  2. Kruskal-Wallis test (two-sided).
\